Sanofi

Lead Pharma Holding B.v.

Lead Pharma B.v.

Cosimo Damiano Cadicamo

Joseph Maria Gerardus Barbara Cals

Sander Bernardus Nabuurs

Vera De Kimpe

Jaap Gerardus Henricus Lemmers

Compounds according to Formula I: or a pharmaceutically acceptable salt thereof wherein: Ais NRor CR, with Rbeing H or methyl, with methyl, if present, optionally being substituted with one or more F; the cyclopropyl moiety can be optionally substituted with one or more methyl and one or more F; A-Aare N or CR-CR, respectively, with the proviso that no more than two of the four positions A in A-Acan be simultaneously N; R-Rare independently H, halogen, amino, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl; Rand Rare independently H, F, methyl, ethyl, hydroxyl or methoxy or Rand Rtogether is carbonyl, all alkyl groups, if present, optionally being substituted with one or more F; Ris H or C(1-6)alkyl; Ris selected from the group consisting of Formula II, III, IV and V  The compounds can be used as inhibitors of ROR&#x3b3; and are useful for the treatment of ROR&#x3b3; mediated diseases.

Growing community of inventors

Oss, Netherlands

Cosimo Damiano Cadicamo